Compare Axogen Inc (AXGN) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.

The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.

REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $77.52, down 1.19% today. The technical outlook is bullish based on moving averages, with a neutral oscillator reading. Recent news highlights U.S. efforts to build rare earth supply chain independence, with construction starting on Energy Fuels' Utah plant expansion (Forbes, 2026-08-04). The ETF provides exposure to 38 global rare earth companies but exhibits high volatility (~50% annualized) and turnover.

The long-term outlook for REMX is supported by geopolitical shifts and demand for critical minerals in technology and defense. However, risks include high volatility, China's dominance in the sector, and sensitivity to trade policies. Investors should weigh the growth potential against the ETF's speculative nature and lack of traditional fundamental metrics like P/E or P/S ratios.